

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>C12N 5/00, 11/00, 11/02, C12M 3/00, 3/04</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 98/22573</b> (43) International Publication Date: <b>28 May 1998 (28.05.98)</b></p>
<p>(21) International Application Number: <b>PCT/US97/21088</b> (22) International Filing Date: <b>18 November 1997 (18.11.97)</b> (30) Priority Data: <b>08/753,104</b>      <b>20 November 1996 (20.11.96)</b>      <b>US</b> (71) Applicant: <b>ADVANCED TISSUE SCIENCES, INC. [US/US];</b> <b>10933 North Torrey Pines Road, La Jolla, CA 92037-1005</b> <b>(US).</b> (72) Inventors: <b>SELIK TAR, Dror; 3181 Paces Station Ridge, At-</b> <b>lanta, GA 30339 (US). DUNKELMAN, Noushin; 11518</b> <b>Mesa Madera Court, San Diego, CA 92131 (US). PETER-</b> <b>SON, Alvin, E.; 17620 Skyline Truck Terrace, Jamul, CA</b> <b>91935 (US). SCHREIBER, Rhonda, E.; 25745 Caryn Court,</b> <b>Ramona, CA 92065 (US). WILLOUGHBY, Jane; 13731</b> <b>Nob Avenue, Del Mar, CA 92014 (US). NAUGHTON,</b> <b>Gail, K.; 1280 Leneta Drive, Del Mar, CA 92014 (US).</b> (74) Agents: <b>CORUZZI, Laura, A. et al.; Pennic &amp; Edmonds, LLP,</b> <b>1155 Avenue of the Americas, New York, NY 10036 (US).</b></p>	<p>(81) Designated States: <b>AL, AM, AU, AZ, BA, BB, BG, BR, BY,</b> <b>CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KG,</b> <b>KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN,</b> <b>MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR,</b> <b>TT, UA, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW,</b> <b>SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ,</b> <b>MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK,</b> <b>ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI</b> <b>patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,</b> <b>SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i> <i>With amended claims.</i></p>	

(54) Title: APPLICATION OF SHEAR FLOW STRESS TO CHONDROCYTES

(57) Abstract

A bioreactor and method are provided for application of shear flow stress of about 1 to about 100 dynes/cm<sup>2</sup> to cultured mammalian cells used for production of artificial cartilage. The bioreactor can be a circulating flow system (16) containing a media reservoir (9), a pump (10), a growth chamber (11) containing a substrate such as a monolayer supporting surface or a 3-dimensional scaffold, and tubing (12). Shear flow stress can be applied by growing a chondrocyte monolayer on the surface of a rotating drum or rotating disc immersed in liquid growth medium, by growing a chondrocyte monolayer on static plates past which a liquid growth medium is pumped, or by establishing chondrocytes in a 3-dimensional scaffold and pumping liquid growth medium through the scaffold. Application of flow shear stress increases the ratio of type II to type I cartilage produced by cultured chondrocytes, and enhances maintenance of chondrocyte phenotype.



BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

APPLICATION OF SHEAR FLOW STRESS TO CHONDROCYTESField of the Invention

5           This invention relates to mammalian tissue culture and artificial cartilage.

Background of the Invention

          Cartilage enables joints to move smoothly. Cartilage consists essentially of highly specialized cells  
10   know as chondrocytes, surrounded by a dense extracellular matrix (ECM). In the case of articular cartilage, the tissue is formed primarily from type II collagen, proteoglycans, and water. Fully matured cartilage has a  
15   limited capacity for regrowth and repair in response to damage from trauma or degenerative joint disease. Surgical procedures have been developed for replacement of damaged cartilage with cartilage grown in tissue culture. Bioreactors are used to grow cultured cells, e.g.,  
20   chondrocytes, for use in generating tissue-engineered cartilage.

Summary of the Invention

          We have discovered that cultured chondrocytes do not align under shear flow stress. We have also discovered that  
25   application of shear flow stress to cultured chondrocytes enhances maintenance of chondrocyte phenotype. This is reflected by enhanced type II collagen deposition in the chondrocytes.

          Based on these discoveries, the invention features a bioreactor for producing artificial cartilage. The  
30   bioreactor includes a growth chamber for housing cultured

mammalian cells, a substrate for attachment of the cells, and means for applying shear flow stress. The bioreactor applies shear flow stress at a level between about 1 and about 100 dynes/cm<sup>2</sup>, and preferably, it can apply shear flow stress at a level between about 1 and about 50 dynes/cm<sup>2</sup>. In some embodiments of the invention, the shear flow stress is applied by means of a reservoir, a pump, and interconnecting tubing. These components are arranged to allow continuous flow of liquid growth medium from the reservoir, through the growth chamber, and back to the reservoir, in response to force applied by the pump.

The substrate in the bioreactor can be a scaffold that supports the growth of a 3-dimensional cell culture. The scaffold can be bioabsorbable. Alternatively, the substrate can be a nonporous surface that supports the growth of cultured cells in a monolayer. The nonporous surface can be the smooth surface of a rotatable drum, a rotatable disc, or a static plate. When a drum or disc is used, shear flow stress is generated by movement, i.e., rotation, of the drum or disc through the liquid culture medium. When a static plate is used, shear flow stress is generated by movement of the liquid culture medium past the plate under force from a pump.

The invention also provides a method for producing artificial cartilage. The method includes the steps of: (a) providing a growth chamber containing a substrate for attachment of cells; (b) bathing the substrate with a liquid growth medium; (c) inoculating into the medium chondrocytes, chondrocyte stem cells, or cells that transdifferentiate into a chondrocyte phenotype; (d) allowing the cells to attach to the substrate; (e) applying and maintaining shear flow stress between about 1 and about 100 dynes/cm<sup>2</sup> to the cells, preferably between about 1 and about 50 dynes/cm<sup>2</sup>;

and (f) culturing the shear flow stressed cells for a time sufficient to produce artificial cartilage.

5 The substrate can be a scaffold, and the scaffold can be bioabsorbable. The substrate can also be a nonporous surface such as a rotatable drum, a rotatable disk, or a static plate.

10 The shear flow stressed cells grown according to this method display enhanced maintenance of a chondrocyte phenotype. In addition, they produce an extracellular matrix containing an increased ratio of type II collagen to type I collagen.

15 The invention also provides a method for inducing differentiation of stem cells into chondrocytes. The stem cell differentiation method includes the steps of: (a) providing a growth chamber containing a substrate for the attachment of cells; (b) bathing the substrate with a liquid growth medium; (c) inoculating into the medium mammalian stem cells; (d) allowing the stem cells to attach to the substrate; (e) applying and maintaining shear flow stress  
20 between about 1 and about 100 dynes/cm<sup>2</sup>, preferably between about 1 and about 50 dynes/cm<sup>2</sup> to the stem cells; and (f) culturing the stem cells for a time sufficient to allow them to differentiate into chondrocytes.

25 The invention also features a method for inducing transdifferentiation of cultured cells into chondrocytes. The transdifferentiation method comprises the steps of: (a) providing a growth chamber containing a substrate for attachment of cells; (b) bathing the substrate with a liquid growth medium; (c) inoculating into the medium mammalian  
30 cells other than chondrocytes or chondrocyte stem cells; (d) allowing the cells to attach to the substrate; (e) applying and maintaining shear flow stress between about 1 and about 100 dynes/cm<sup>2</sup>, preferably between about 1 and about 50

dynes/cm<sup>2</sup>, to the cells; and (f) culturing the cells for a time sufficient to allow them to transdifferentiate into chondrocytes. Preferred nonchondrocyte cell types for use in this transdifferentiation method are fibroblasts and myocytes.

As used herein, "bioabsorbable" means biodegradable in cell culture or in the body of an artificial cartilage transplant recipient.

As used herein, "chondrocyte" means a cartilage cell. Chondrocytes are found in various types of cartilage, e.g., articular (or hyaline) cartilage, elastic cartilage, and fibrocartilage.

As used herein, "substrate" means a supporting structure to which cultured cells anchor or attach, in a growth chamber.

As used herein, "scaffold" means a 3-dimensional, porous, cell culture-compatible structure, throughout which cultured mammalian cells can attach so as to form a 3-dimensional culture. As the terms are used herein, a scaffold is a type of substrate.

As used herein, "shear flow stress" means a fluid-borne force acting on cultured cells due to relative movement between a liquid culture medium and the cells. Shear flow stress can be generated by moving liquid past static cells, moving cells through static liquid, or by moving the liquid and the cells simultaneously. Shear flow stress is generally quantified in terms of dynes/cm<sup>2</sup>.

As used herein, "stem cell" means an undifferentiated cell which generates daughter cells that will mature into the specialized cells characterizing a particular tissue.

As used herein, "transdifferentiation" means the change of a differentiated cell from one phenotype, e.g.,

myoblast or fibroblast, into another phenotype, e.g., a chondrocyte.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one skilled in the art of cell culturing techniques. Although materials and methods similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other advantages and features of the invention will be apparent from the detailed description, and from the claims.

#### Brief Description of the Drawings

Fig. 1 is a diagrammatic representation of a shear flow bioreactor system that includes a growth chamber, a pump, a media reservoir, and connective tubing.

Fig. 2 is a diagrammatic representation of a shear flow growth chamber that contains concentric inner and outer drums at least partially submerged in liquid culture medium.

Fig. 3 is a diagrammatic representation of a shear flow growth chamber that contains a disk that rotates within the growth chamber.

Fig. 4 is a diagrammatic representation of a shear flow growth chamber that contains static parallel plates inside the growth chamber.

Fig. 5 is a bar graph summarizing data on collagen and sulfated GAG levels in artificial cartilage constructs

at two weeks and four weeks. White bars, sulfated GAG; black bars, collagen.

Fig. 6 is a bar graph summarizing data on collagen and sulfated GAG levels in artificial cartilage constructs at two weeks, four weeks, and in native cartilage. White bars, sulfated GAG; black bars, collagen.

#### Detailed Description

The present invention provides apparatuses and methods for applying shear flow stress to mammalian cell cultures used for artificial cartilage production.

Applying shear flow stress to a three-dimensional or monolayer chondrocyte culture advantageously increases the ratio of type II to type I collagen produced by the chondrocytes. The shear flow stress also advantageously enhances maintenance of the chondrocyte phenotype. Thus, application of shear flow stress according to this invention improves the functional outcome of a three-dimensional or monolayer chondrocyte culture and increases the useful lifetime of the monolayer culture.

Applying shear flow stress to stem cells induces or promotes differentiation of the stem cells into chondrocytes. Inducing or promoting stem cells to differentiate into chondrocytes is accomplished by substituting stem cells for chondrocytes in the shear flow method described herein with regard to chondrocytes. The chondrocytes arising from the stem cell differentiation process are maintained in the culture, under shear flow stress, for a sufficient time to allow production of artificial cartilage.

Shear flow stress also can be used according to this invention to induce transdifferentiation of differentiated cells into chondrocytes. Transdifferentiation is

accomplished by substituting, differentiated cells other than chondrocytes, e.g., myoblasts or fibroblasts, in the shear flow method described herein with regard to chondrocytes. In response to the shear flow stress, the differentiated cells transdifferentiate into chondrocytes. The chondrocytes arising from the transdifferentiation process are maintained in the culture, under shear flow stress, for a sufficient time to allow production of artificial cartilage.

Artificial cartilage produced according to any embodiment of this invention can be used for surgical transplantation, according to established medical procedures, to replace damaged or missing cartilage. Typically, artificial cartilage is employed in the repair of human joints, e.g., knees and elbows.

In the apparatuses and methods of this invention, shear flow stress can be applied to the cultured cells by various means. For example, shear flow stress can be applied by growing a chondrocyte monolayer on the surface of a rotating drum or rotating disc immersed in liquid growth medium. Alternatively, shear flow stress can be applied by growing a chondrocyte monolayer on static plates past which liquid growth medium is pumped. Shear flow stress can also be applied to a 3-dimensional chondrocyte culture by establishing the culture in a chamber through which liquid growth medium is pumped.

The amount of shear flow stress applied to the chondrocytes is controlled by adjusting the rate of rotation of the drum or disc, or adjusting the liquid medium pumping rate. In this invention, the level of shear flow stress applied to the chondrocytes or other cells is between about 1 and about 100 dynes/cm<sup>2</sup>. Preferably, the shear flow

stress is between about 1 and about 50 dynes/cm<sup>2</sup>. Shear flow stress is calculated according to equation (1):

$$\text{shear flow stress} = \tau = 6\mu Q/bh^2 \text{ dynes/cm}^2$$

where:

- 5             $\mu$  = viscosity of fluid (N sec/m<sup>2</sup>);  
             Q is flow rate (ml/min);  
             b = chamber width (cm); and  
             h = chamber height (cm).

#### Cultured Chondrocytes

- 10            Preferably, the cultured chondrocytes are anchored, i.e., attached, to a substrate, whether grown as a monolayer or grown in a 3-dimensional culture. A monolayer-supporting surface, or a 3-dimensional scaffold, in a bioreactor is inoculated with chondrocytes, stem cells, or differentiated  
15 cells suitable for transdifferentiation. Artificial cartilage can be produced by growing chondrocytes in a conventional mammalian tissue culture medium, e.g., RPMI 1640, Fisher's, Iscove's or McCoy's. Such media are well known in the art, and are commercially available.  
20 Typically, the cells are cultured at 37°C in air supplemented with 5% CO<sub>2</sub>. Under these conditions, a chondrocyte monolayer or a three dimensional cartilage matrix is produced in approximately 7 to 56 days, depending on the cell type used for inoculation and the culture  
25 conditions.

Isolated chondrocytes can be used to inoculate the reactor surface or 3-dimensional matrix. Alternately, stem cells, or cells suitable for transdifferentiation can be used for inoculation.

- 30            Cells used for inoculation of cultures used in the present invention can be isolated by any suitable method. Various starting materials and methods for chondrocyte

isolation are known. See generally, Freshney, Culture of Animal Cells. A Manual of Basic Techniques, 2d ed., A.R. Liss Inc., New York, pp137-168 (1987). Examples of starting materials for chondrocyte isolation include mammalian knee joints or rib cages.

If the starting material is a tissue in which chondrocytes are essentially the only cell type present, e.g., articular cartilage, the cells can be obtained directly by conventional collagenase digestion and tissue culture methods. Alternatively, the cells can be isolated from other cell types present in the starting material. One known method for chondrocyte isolation includes differential adhesion to plastic tissue culture vessels. In a second method, antibodies that bind to chondrocyte cell surface markers can be coated on tissue culture plates and then used to selectively bind chondrocytes from a heterogeneous cell population. In a third method, fluorescence activated cell sorting (FACS) using chondrocyte-specific antibodies is used to isolate chondrocytes. In a fourth method, chondrocytes are isolated on the basis of their buoyant density, by centrifugation through a density gradient such as Ficoll.

Examples of tissues from which stem cells for differentiation, or differentiated cells suitable for transdifferentiation, can be isolated include placenta, umbilical cord, bone marrow, skin, muscle, periosteum, or perichondrium. Cells can be isolated from these tissues by explant culture and/or enzymatic digestion of surrounding matrix using conventional methods.

When the artificial cartilage construct has grown to the desired size and composition, a cryopreservative fluid can be introduced into the system. The cryopreservative fluid freezes the artificial cartilage construct for future use. Cryopreservation methods and materials for mammalian

tissue culture material are known to those of ordinary skill in the art.

#### Bioreactor Flow System

5 In some embodiments of this invention, as shown in Fig. 1, a circulating flow system 16 is used with a growth chamber 11. The circulating flow system 16 includes a media reservoir 9, a pump 10, a growth chamber 11, and tubing 12.

Any sterilizable liquid container can be adapted for use as a reservoir 9. One type of preferred reservoir  
10 is a sterile bag. Suitable sterile bags are commercially available, e.g., from Gibco/BRL. In some embodiments of the invention, an upper reservoir is placed upstream of the bioreactor, a lower reservoir is placed downstream of the bioreactor, and the pump returns liquid medium from the  
15 lower reservoir to the upper reservoir.

The reservoir 9 can include a sterile filter to provide a direct source of sterile gas to the liquid in the system. Alternatively, the reservoir 9 can include gas permeable tubing or membranes made of silicone or Teflon,  
20 e.g., to provide an indirect source of sterile gas to the system via diffusion. Preferably, one or more valves and a flow meter are included in the flow system.

The pump 10 is designed to transfer liquid from the reservoir 9 to the growth chamber 11, and return it, under  
25 sterile conditions. Typically, the pump 10 controls both the flow rate and pressure within the system. The pump 10 can be a peristaltic pump. Alternatively, an elastomeric bladder with an alternating pressure source can be used. Varying the external pressure causes the bladder to inflate  
30 and deflate. A pair of check valves can be used to achieve unidirectional movement of sterile fluid in the system.

The connective tubing 12 for circulating the sterile liquid within the system can be stainless steel pipe, or durable medical-grade plastic tubing. Alternatively, the tubing 12 can be a gas-permeable material such as silicone.

5    3-Dimensional Cultures

Methods and materials for 3-dimensional cultures of mammalian cells are known in the art. See, e.g., U.S. Patent No. 5,266,480. Typically, a scaffold is used in a bioreactor growth chamber to support a 3-dimensional culture. The scaffold can be made of any porous, tissue culture-compatible material into which cultured mammalian cells can enter and attach or anchor. Such materials include nylon (polyamides), dacron (polyesters), polystyrene, polypropylene, polyacrylates, polyvinyl chloride, polytetrafluoroethylene (teflon), nitrocellulose, and cotton. Preferably, the scaffold is a bioabsorbable or biodegradable material such as polyglycolic acid, catgut suture material, or gelatin. In general, the shape of the scaffold is not critical.

20    Optionally, prior to inoculating chondrocytes into the scaffold, stromal cells are inoculated into the scaffold and allowed to form a stromal matrix. The chondrocytes are then inoculated into the stromal matrix. The stromal cells can include fibroblasts. The stromal cells can also include other cell types.

25    A 3-dimensional culture can be used in a circulating flow system 16 such as that depicted schematically in Fig. 1. Shear flow stress is applied to the chondrocytes by the movement of liquid culture medium pumped through the growth chamber, which contains the 3-dimensional culture. Preferably, the scaffold and attached cells are static.

Data obtained from two bioreactor systems, Apollo and Gemini I, show that increasing flow rates i.e., increasing shear stress, improves chondrocyte performance in 3-dimensional cultures used to produce artificial cartilage.

5        Apollo Bioreactor

Articular cartilage was aseptically harvested from the femoral/tibial joints of skeletally mature New Zealand white rabbits within 4 hr post-sacrifice. Chondrocytes were isolated by collagenase digestion as described by Dunkelman et al. (*Biotech. Bioengineering* 46:299-305 (1995)). They were then grown for two passages in culture medium (DMEM containing 10% fetal bovine serum, 2 mM L-glutamine, 2 mM nonessential amino acids, 50 mg/mL proline, 1 mM sodium pyruvate, and 35 mg/mL gentamycin).

15        Injection molded, polycarbonate bioreactors (1.2 mL internal volume) were assembled using gas permeable silicone and bioprene tubing and sterilized by electron-beam radiation (2.5 Mrad). Polyglycolic acid (PGA) mesh (52 mg/cc, non-heat plated, 1.9 mm thick, 1 cm diameter, 20        porosity 97% void volume) were sterilized by ethylene oxide gas and stored under nitrogen until use. The sterile PGA mesh were presoaked in culture medium overnight at 37°C and placed in sterile bioreactor systems.

The mesh were seeded using a recirculating seeding 25        technique in which each bioreactor system (5 tandem bioreactors) was attached to a media bag containing a cell suspension of  $30 \times 10^6$  cells in 35 mL of culture medium. The system was connected to a pump (Cole-Parmer) to obtain a culture medium flow rate of 0.2 mL/min, and placed in a 30        humidified incubator at 37°C. After seeding, constructs were cultured with media containing ascorbate (50 µg/mL), at a flow rate of 0.05 mL/min. After overnight incubation, the flow rate increased to 0.2 mL/min, then weekly in increments

of 0.2 mL/min. Flow direction changed 5 days per week.

After two or four weeks of culture, the cartilage constructs were analyzed for total sulfated glycosaminoglycans (GAGs) by dimethylmethylen blue binding as described by Farndale et al. (*Biochem. Biophys. Acta* 883:173-177 (1986)). Total collagen was analyzed by hydroxyproline quantification as described by Woessner et al. (*Arch. Biochem. Biophys.* 93:440-447 (1961)). Separate samples were harvested, fixed in 10% buffered formalin, and paraffin embedded. Five micron sample sections were stained with Safranin O or collagen antibodies (Southern Biotech, Birmingham, AL) to assess the quantity and distribution of sulfated glycosaminoglycans (GAG) and collagen types, respectively.

Between two and four weeks of culture in hydrodynamic conditions, a significant increase ( $p < 0.05$ ) in the levels, as well as the percentage of collagen and sulfated-GAG on the cartilage constructs was observed (Figs. 5 and 6). At four weeks, the concentrations were not significantly different than those in adult rabbit articular cartilage (Fig. 6). Although collagen levels increased between two and four weeks of culture, at four weeks the collagen content was still below that of rabbit articular cartilage. In comparison to these hydrodynamically grown constructs less collagen and sulfated-GAG was present in cultures held statically for the same time periods.

Histologically, the pattern of sulfated-GAG deposited on constructs grown under hydrodynamic conditions was similar to that of native rabbit articular cartilage, while that of statically grown constructs was non-uniform, with little sulfated-GAG in the construct's center. Type II collagen was present in immunostained constructs with a similar distribution to that seen in native articular

cartilage. Lacunae surrounded the majority of cells in hydrodynamically but not statically held constructs.

#### Gemini I Bioreactor

Similar results were obtained in experiments carried out using a scaled up bioreactor. Rabbit chondrocytes were seeded at  $30 \times 10^6$  cells/system, and either grown at 0.05 ml/min constant flow rate, or at a flow rate gradually increased from 0.05 to 0.8 ml/min. The cell grown under the increased flow rate showed higher matrix deposition. In cultures grown at the increased flow rate, glycosaminoglycan (GAG) levels were from 25% to 50%, whereas in comparable cells grown at the low flow rate (0.05 ml/min), GAG levels were approximately 3%. In cultures grown at the increased flow rate, collagen levels were from 12% to 20%, whereas in comparable cells grown at the low flow rate (0.05 ml/min), collagen levels were approximately 5%.

#### Monolayer Cultures

Bioreactors can be designed in a number of ways to produce shear flow stress on a chondrocyte monolayer. This induces and maintains the chondrocyte phenotype.

Fig. 2 schematically illustrates a shear flow growth chamber 3 that includes concentric drums 1, 2. The surface of either drum 1, 2, or both, can serve as a substrate for the attachment of cells. One of the drums can remain stationary while the other drum rotates. Alternatively, both drums can rotate. In either arrangement, the drums 1, 2 are at least partially submerged in liquid growth medium 15. The relative movement between the drum-anchored cells and the liquid growth medium 15 generates shear flow stress.

The amount of flow stress applied to the cells can be adjusted by adjusting drum rotation speed according to

equation (1) above. The distance 13 between the drums 1, 2 is parameter (h) in equation (1). Preferably, drum rotation speed is selected to achieve a shear flow stress from about 1 to about 100 dynes/cm<sup>2</sup>, and more preferably from about 1 to about 50 dynes/cm<sup>2</sup>. Preferably, the drum is rotated by means of a variable speed electric motor. The optimal distance between the two drums depends on various factors, including the drum size and the material from which they are made. Determination of the optimal drum configuration is within ordinary skill in the art. Because shear flow stress is generated by the drum's rotation, a continuous flow arrangement involving a liquid reservoir and pump is optional.

Fig. 3 schematically illustrates a shear flow growth chamber 5 that includes a rotating disc 4 in the growth chamber 5. The disc 4 is immersed in liquid culture medium 15, where it serves as a substrate for attachment of cells. The amount of flow stress applied to the cells can be adjusted by adjusting disc rotation speed according to equation (1) above. The distance 13 between the disk 4 and the growth chamber wall is parameter (h) in equation (1). Preferably, disc rotation speed is selected to achieve a shear flow stress from about 1 to about 100 dynes/cm<sup>2</sup>, and more preferably from about 1 to about 50 dynes/cm<sup>2</sup>. Optionally, a multiplicity of discs can be placed on a single rotating shaft to increase the total surface area available to support cell attachment and growth. Typically, the disc is rotated by means of a variable speed electric motor. Because shear flow stress is generated by the disc rotation, a continuous flow arrangement involving a liquid reservoir and pump is optional.

Cells located near the periphery of the rotating disc move at a greater speed than cells located near the

central shaft. Therefore, they are subjected to a greater shear flow stress. The magnitude of this effect depends on disc size. Thus, the rotating disc embodiment of the invention permits simultaneous growth of cells exposed to a continuous range of shear flow stress levels within a single bioreactor. This feature can be exploited for systematic comparison of the effect of varying shear flow stress levels on a given type of cell in a given culture medium.

Fig. 4 schematically illustrates a shear flow growth chamber 8 that includes two parallel, static plates or walls 6 and 7 inside the growth chamber 8. A single pair of static plates 6, 7 can be used, or more than one pair can be used in the same growth chamber 8. Because the plates 6, 7 are static, shear flow stress is generated solely by the movement of liquid culture medium 15 pumped through the chamber 8. The liquid culture medium 15 is pumped past the parallel plates 6 and 7, to create a shear flow stress between about 1 and about 100 dynes/cm<sup>2</sup>, and preferably between about 1 and about 50 dynes/cm<sup>2</sup>. Shear flow stress is adjusted by adjusting liquid culture medium 15 flow rate in accordance with equation (1) above. The distance 13 between the static plates 6, 7 is parameter (h) in equation (1). The static plates 6, 7 are preferably parallel to each other, and at right angles to the prevailing flow of liquid growth medium 15.

The advantage of increasing the number of plates 6, 7 is greater total surface area on which cells can form a monolayer. The potential disadvantage of multiple plates is that as the number of plates increases, it may become relatively more difficult to maintain an even level of shear flow stress on cells throughout the chamber 8. One way of maintaining an even level of shear flow stress is to disperse the entering liquid culture medium 15a over a wide

area on one wall of the chamber 8 while collecting the exiting liquid culture medium 15b from a similarly wide area on the opposite wall of the chamber.

The rotating drums 1, 2, rotating disc 4, or static plates 6, 7 must be made of a tissue culture compatible material. Various tissue culture compatible materials are known, e.g., polystyrene, polycarbonate, and stainless steel. Selection of a suitable material for the walls of the growth chamber and the monolayer-supporting substrate is within ordinary skill in the art.

In experiments described below, liquid flow rate in a bioreactor was adjusted to obtain preselected shear flow stress levels of approximately 1 dyne/cm<sup>2</sup> and approximately 24 dynes/cm<sup>2</sup>. Viscosity ( $\mu$ ) of the liquid culture medium was 0.0012 N sec/m<sup>2</sup>; chamber width (b) was 2.5 cm; and chamber height (h) was 0.025 cm. Using equation (1) above, it was calculated that for a shear flow stress of 1 dyne/cm<sup>2</sup>, flow rate (Q) should be 1.3 ml/min. It was calculated that for a shear flow stress of 24 dynes/cm<sup>2</sup>, flow rate (Q) should be 31.25 ml/min.

For seeding of chondrocytes, plates (7.5 cm by 3.75 cm) were cut from large tissue culture dishes. The plates were sterilized by treatment with 70% ethanol, followed by a 1-hour treatment with ultraviolet light in a laminar flow hood. The plates were then placed in petri dishes and plated with a 1 ml suspension of passage 2 rabbit chondrocytes, at a density of approximately 100,000 cells per plate. Cell culture medium used in this procedure was complete medium without ascorbate. The plates were covered in medium and allowed to stand for 6 hours. They were then transferred to an incubator for 2 days at 37°C. Approximately 15 ml of additional medium was added, and the

plates were placed in the flow loop. At this stage, the cells were subconfluent.

Experiments were carried out to compare results obtained at low and high flow rates in this system. A low flow rate, which generated 1 dyne/cm<sup>2</sup>, was used with chondrocytes at a density comparable to the density used in a shear stress roller bottle apparatus operating at 1 rpm. A high flow rate, which generated 24 dynes/cm<sup>2</sup> was also tested, for comparison.

The results demonstrated a shear flow stress-dependent difference in chondrocyte collagen production. At 24 dynes/cm<sup>2</sup>, production of type I collagen was diminished, in comparison to the static roller bottle results. At 24 dynes/cm<sup>2</sup>, production of type II collagen was enhanced, in comparison to the static roller bottle results. Under the shear stress conditions in these experiments, there was no orientation of the cells in the direction of flow.

Other embodiments are within the following claims.

Claims

We claim:

1           1. A bioreactor for producing artificial cartilage,  
2 comprising a growth chamber, a substrate, and means for  
3 applying shear flow stress of about 1 to about 100 dynes/cm<sup>2</sup>  
4 to cells attached to said substrate.

1           2. The bioreactor of claim 1, further comprising a  
2 means for applying shear flow stress of about 1 to about 50  
3 dynes/cm<sup>2</sup>.

1           3. The bioreactor of claim 1, wherein said means  
2 for applying shear flow stress comprises a reservoir, a  
3 pump, and tubing interconnecting said growth chamber, said  
4 reservoir, and said pump, so as to allow continuous flow of  
5 liquid growth medium from said reservoir, through said  
6 growth chamber, and back to said reservoir, in response to  
7 force applied by said pump.

1           4. The bioreactor of claim 1, wherein said  
2 substrate is a scaffold.

1           5. The bioreactor of claim 4, wherein said scaffold  
2 is bioabsorbable.

1           6. The bioreactor of claim 1, wherein said  
2 substrate is a nonporous surface that supports the growth of  
3 said cultured mammalian cells in a monolayer.

1           7. The bioreactor of claim 6, wherein said  
2 nonporous surface is a the surface of a rotatable drum.

1           8. The bioreactor of claim 6, wherein said  
2 nonporous surface is a the surface of a rotatable disc.

1           9. The bioreactor of claim 6, wherein said  
2 nonporous surface is a static plate.

1           10. A method for producing artificial cartilage,  
2 said method comprising the steps of:

3           (a) providing a growth chamber comprising a  
4 substrate;

5           (b) covering said substrate with a liquid growth  
6 medium;

7           (c) inoculating into said medium chondrocytes,  
8 chondrocyte stem cells, or cells that transdifferentiate  
9 into a chondrocytes phenotype;

10          (d) allowing said cells to attach to said substrate;

11          (e) applying and maintaining shear flow stress of  
12 about 1 to about 100 dynes/cm<sup>2</sup> to said cells, thereby  
13 producing shear flow stressed cells; and

14          (f) culturing said shear flow stressed cells for a  
15 time sufficient to produce artificial cartilage.

1           11. The method of claim 10, wherein said shear flow  
2 stress is about 1 to about 50 dynes/cm<sup>2</sup>.

1           12. The method of claim 10, wherein said substrate  
2 is a scaffold.

1           13. The method of claim 12, wherein said scaffold  
2 is bioabsorbable.

1           14. The method of claim 10, wherein said substrate  
2 is a nonporous surface that supports the growth of said  
3 cultured mammalian cells in a monolayer.

1           15. The method of claim 14, wherein said nonporous  
2 surface is a the surface of a rotatable drum.

1           16. The method of claim 14, wherein said nonporous  
2 surface is a the surface of a rotatable disc.

1           17. The method of claim 14, wherein said nonporous  
2 surface is a static plate.

1           18. The method of claim 10, wherein said shear flow  
2 stressed cells:

3           (a) display enhanced maintenance of a chondrocyte  
4 phenotype; and

5           (b) produce an extracellular matrix containing an  
6 enhanced ratio of type II collagen to type I collagen.

1           19. A method for inducing differentiation of stem  
2 cells into chondrocytes, said method comprising the steps  
3 of:

4           (a) providing a growth chamber comprising a  
5 substrate;

6           (b) covering said substrate with a liquid culture  
7 medium;

8           (c) inoculating into said medium mammalian stem  
9 cells;

10          (d) allowing said stem cells to attach to said  
11 substrate;

12          (e) applying and maintaining shear flow stress of  
13 about 1 to about 100 dynes/cm<sup>2</sup> to said stem cells, thereby  
14 producing shear flow stressed stem cells; and

15          (f) culturing said shear flow stressed stem cells  
16 for a time sufficient to allow them to differentiate into  
17 chondrocytes.

1           20. The method of claim 19, wherein said shear flow  
2 stress is about 1 to about 50 dynes/cm<sup>2</sup>.

1           21. A method for inducing transdifferentiation of  
2 cultured cells into chondrocytes, said method comprising the  
3 steps of:

4           (a) providing a growth chamber comprising a  
5 substrate;

6           (b) covering said substrate with a liquid growth  
7 medium;

8           (c) inoculating into said medium mammalian cells  
9 other than chondrocytes or chondrocyte stem cells;

10          (d) allowing said cells to attach to said substrate;

11          (e) applying and maintaining shear flow stress of  
12 about 1 to about 100 dynes/cm<sup>2</sup> to said cells, thereby  
13 producing shear flow stressed cells; and

14          (f) culturing said shear flow stressed cells for a  
15 time sufficient to allow them to transdifferentiate into  
16 chondrocytes.

1           22. The method of claim 21, wherein said shear flow  
2 stress is about 1 to about 50 dynes/cm<sup>2</sup>.

1           23. The method of claim 20, wherein said  
2 differentiated mammalian cells are selected from the group  
3 consisting of fibroblasts and myocytes.

## AMENDED CLAIMS

[received by the International Bureau on 1 April 1998 (01.04.98);  
original claims 1,6-8,10,14-16,19,21 and 23 amended; new claims  
24-31 added; remaining claims unchanged (5 pages)]

- 5           1. A bioreactor for producing cartilage, comprising  
a growth chamber, a substrate for the attachment of cells  
capable of producing cartilage, and means for applying  
relative movement between a liquid culture medium and the  
substrate to provide a shear flow stress of about 1 to about  
10 100 dynes/cm<sup>2</sup> to the cells attached to said substrate.
2. The bioreactor of claim 1, further comprising a  
means for applying shear flow stress of about 1 to about 50  
dynes/cm<sup>2</sup>.
- 15           3. The bioreactor of claim 1, wherein said means for  
applying shear flow stress comprises a reservoir, a pump, and  
tubing interconnecting said growth chamber, said reservoir,  
and said pump, so as to allow continuous flow of liquid  
20 growth medium from said reservoir, through said growth  
chamber, and back to said reservoir, in response to force  
applied by said pump.
4. The bioreactor of claim 1, wherein said substrate  
25 is a scaffold.
5. The bioreactor of claim 1, wherein said scaffold  
is bioabsorbable.
- 30           6. The bioreactor of claim 1, wherein said substrate  
is a nonporous surface that supports the growth of said cells  
in a monolayer.
7. The bioreactor of claim 6, wherein said nonporous  
35 surface is the surface of a rotatable drum.

8. The bioreactor of claim 6, wherein said nonporous surface is the surface of a rotatable disc.

9. The bioreactor of claim 6, wherein said nonporous surface is a static plate.

10. A method for producing cartilage, said method comprising the steps of:

- (a) providing a growth chamber comprising a substrate for cell attachment;
- (b) covering said substrate with a liquid growth medium;
- (c) inoculating into said medium cells capable of producing cartilage;
- (d) allowing said cells to attach to said substrate;
- (e) applying and maintaining relative movement between the liquid growth medium and the cells attached to the substrate to provide a shear flow stress of about 1 to about 100 dynes/cm<sup>2</sup> to said cells, thereby producing shear flow stressed cells; and
- (f) culturing said shear flow stressed cells for a time sufficient to produce cartilage.

11. The method of claim 10, wherein said shear flow stress is about 1 to about 50 dynes/cm<sup>2</sup>.

12. The method of claim 10, wherein said substrate is a scaffold.

13. The method of claim 10, wherein said scaffold is bioabsorbable.

14. The method of claim 10, wherein said substrate is a nonporous surface that supports the growth of said cells in a monolayer.

15. The method of claim 10, wherein said nonporous surface is the surface of a rotatable drum.

16. The method of claim 10, wherein said nonporous surface is the surface of a rotatable disc.

17. The method of claim 10, wherein said nonporous surface is a static plate.

18. The method of claim 10, wherein said shear flow stressed cells:

(a) display enhanced maintenance of a chondrocyte phenotype; and

(b) produce an extracellular matrix containing an enhanced ratio of type II collagen to type I collagen.

19. A method for inducing differentiation of stem cells into chondrocytes, said method comprising the steps of:

(a) providing a growth chamber comprising a substrate for cell attachment;

(b) covering said substrate with a liquid growth medium;

(c) inoculating into said medium mammalian stem cells;

(d) allowing said cells to attach to said substrate;

(e) applying and maintaining relative movement between the liquid growth medium and the cells attached to the substrate to provide a shear flow stress of about 1 to about 100 dynes/cm<sup>2</sup> to said stem cells, thereby producing shear flow stressed stem cells; and

(f) culturing said shear flow stressed stem cells for a time sufficient to allow them to differentiate into chondrocytes.

20. The method of claim 19, wherein said shear flow stress is about 1 to about 50 dynes/cm<sup>2</sup>.

21. A method for inducing transdifferentiation of cultured cells into chondrocytes, said method comprising the steps of:

- (a) providing a growth chamber comprising a  
5 substrate for cell attachment;
- (b) covering said substrate with a liquid growth medium;
- (c) inoculating into said medium mammalian cells other than chondrocytes or chondrocyte stem cells;
- 10 (d) allowing said cells to attach to said substrate;
- (e) applying and maintaining relative movement between the liquid growth medium and the cells attached to the substrate to provide a shear flow stress of about 1 to  
15 about 100 dynes/cm<sup>2</sup> to said cells, thereby producing shear flow stressed cells; and
- (f) culturing said shear flow stressed cells for a time sufficient to allow them to transdifferentiate into chondrocytes.

20

22. The method of claim 21, wherein said shear flow stress is about 1 to about 50 dynes/cm<sup>2</sup>.

23. The method of claim 21, wherein said  
25 differentiated mammalian cells are selected from the group consisting of fibroblasts and myocytes.

24. The bioreactor of claim 1, wherein the cells are selected from the group consisting of chondrocytes,  
30 chondrocyte stem cells, mesenchymal stem cells, and cells that transdifferentiate into a chondrocyte phenotype.

25. The bioreactor of claim 4, wherein the scaffold is biocompatible.

35

26. The bioreactor of claim 25, wherein the scaffold is biodegradable.

27. The bioreactor of claim 25, wherein the scaffold is non-biodegradable.

28. The method of claim 10, wherein the cells are selected from the group consisting of chondrocytes, chondrocyte stem cells, mesenchymal stem cells, and cells that transdifferentiate into a chondrocyte phenotype.

29. The method of claim 12, wherein the scaffold is biocompatible.

30. The method of claim 29, wherein the scaffold is biodegradable.

31. The method of claim 29, wherein the scaffold is non-biodegradable.

20

25

30

35

1/4






FIG. 1



3  
FIG. 2



5  
13  
FIG. 3

3/4




FIG. 4

4/4




FIG. 5




FIG. 6

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/21088

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 5/00, 11/00, 11/02; C12M 3/00, 3/04

US CL : 435/395, 174, 177, 397, 402, 289.1, 298.2

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/395, 174, 177, 397, 402, 289.1, 298.2

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CAS, BIOSIS, MEDLINE

search terms: shear flow stress, bioreactor, chondrocytes, cartilage

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,041,138 A (VACANTI et al.) 20 August 1991, entire document.	1-23
Y	WO 94/25584 A1 (JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE) 10 November 1994, entire document.	1-23
Y	WO 93/01843 A1 (UNIVERSITY OF LEICESTER) 04 February 1993, entire document.	7, 8, 15, 16



Further documents are listed in the continuation of Box C.



See patent family annex.

Special categories of cited documents:	
*A* document defining the general state of the art which is not considered to be of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*B* earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means	*Z* document member of the same patent family
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

22 JANUARY 1998

Date of mailing of the international search report

17 FEB 1998

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DAVID B. NAPP

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

Inter. onal Application No  
PCT/CA 99/00156

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 A61N5/06				
According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 A61N				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	US 5 616 140 A (PRESCOTT MARVIN) 1 April 1997 see column 4, line 55 - column 5, line 10 see column 5, line 63 - column 7, line 20 see column 14, line 64 - column 15, line 9	1-9, 14-18		
X	FR 2 591 902 A (COLLIN YVON) 26 June 1987  see page 5, line 1 - page 6, line 22	1-5, 7, 8, 10, 11, 13-18		
X	DE 296 12 198 U (WILDEN LUTZ DR MED) 12 September 1996  see page 3, line 23 - page 6, line 8	1-5, 7-12, 14-18		
<input type="checkbox"/> Further documents are listed in the continuation of box C.				
<input checked="" type="checkbox"/> Patent family members are listed in annex.				
<b>* Special categories of cited documents:</b>				
<table border="0"> <tr> <td style="vertical-align: top;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </td> </tr> </table>			<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>
<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>			
Date of the actual completion of the international search  3 June 1999		Date of mailing of the international search report  11/06/1999		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3018		Authorized officer  Petter, E		

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/00156

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 19  
because they relate to subject matter not required to be searched by this Authority, namely:  
Rule 39.1(iv) PCT - method for treatment of the human or animal body by therapy
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00156

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5616140 A	01-04-1997	AU 2104195 A WO 9525563 A	09-10-1995 28-09-1995
FR 2591902 A	26-06-1987	NONE	
DE 29612198 U	12-09-1996	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**